Scientific review of protocols to enhance informativeness of global health clinical trials.

ABSTRACT:

Background

Trial informativeness describes the likelihood of a clinical trial to have a meaningful impact on clinical practice, research, or policy decisions. A dedicated scientific review process for protocols at the post-funding stage is not common, yet is an opportunity to enhance trial informativeness. The Bill and Melinda Gates Foundation (BMGF), one of the largest funders of clinical trials, created a group called Design, Analyze, Communicate (DAC). DAC's first completion of an expert scientific review of a grantee's trial protocol was in 2020. We categorized and quantified areas of scientific review feedback provided for 52 clinical trial protocols submitted to DAC over a 3-year period. Most trials planned to study treatment interventions and included at least one trial site

SUBMITTER: Burford B 

PROVIDER: S-EPMC11899556 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature